WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, f inds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States, according to surveyed U.S. and European neurologists.
. Posting comments can be beneficial to others and it allows you to express yourself. If you have a statement or question pertaining to this article, this is the place to leave it. Click the link below the article that reads: Post Comments. - Thank You ============================================